161 related articles for article (PubMed ID: 15041715)
1. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Baker SD; Zhao M; Lee CK; Verweij J; Zabelina Y; Brahmer JR; Wolff AC; Sparreboom A; Carducci MA
Clin Cancer Res; 2004 Mar; 10(6):1976-83. PubMed ID: 15041715
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
Garcia AA; Pujari M; Jeffers S; Iqbal S; Lenz HJ; Beringer P; Louie S
Cancer Chemother Pharmacol; 2005 Jul; 56(1):75-82. PubMed ID: 15809878
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
Murren JR; Peccerillo K; DiStasio SA; Li X; Leffert JJ; Pizzorno G; Burtness BA; McKeon A; Cheng Y
Cancer Chemother Pharmacol; 2000; 46(1):43-50. PubMed ID: 10912577
[TBL] [Abstract][Full Text] [Related]
6. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
[TBL] [Abstract][Full Text] [Related]
7. Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study.
Briasoulis E; Pentheroudakis G; Timotheadou H; Rammou D; Pavlidis N; Fountzilas G
Anticancer Drugs; 2004 Sep; 15(8):747-52. PubMed ID: 15494635
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
Chest; 2006 Apr; 129(4):1031-8. PubMed ID: 16608954
[TBL] [Abstract][Full Text] [Related]
9. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Masi G; Falcone A; Di Paolo A; Allegrini G; Danesi R; Barbara C; Cupini S; Del Tacca M
Clin Cancer Res; 2004 Mar; 10(5):1657-63. PubMed ID: 15014016
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study.
Schrijvers D; Pronk L; Highley M; Bruno R; Locci-Tonelli D; De Bruijn E; Van Oosterom AT; Verweij J
Am J Clin Oncol; 2000 Aug; 23(4):358-63. PubMed ID: 10955864
[TBL] [Abstract][Full Text] [Related]
12. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
Gustafson DL; Long ME; Zirrolli JA; Duncan MW; Holden SN; Pierson AS; Eckhardt SG
Cancer Chemother Pharmacol; 2003 Aug; 52(2):159-66. PubMed ID: 12759775
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Herben VM; Schellens JH; Swart M; Gruia G; Vernillet L; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1897-905. PubMed ID: 10561231
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
Slaviero KA; Clarke SJ; McLachlan AJ; Blair EY; Rivory LP
Br J Clin Pharmacol; 2004 Jan; 57(1):44-53. PubMed ID: 14678339
[TBL] [Abstract][Full Text] [Related]
15. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer.
Fujita K; Yoshino E; Kawara K; Maeda K; Kusuhara H; Sugiyama Y; Yokoyama T; Kaneta T; Ishida H; Sasaki Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):793-801. PubMed ID: 26297058
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
[TBL] [Abstract][Full Text] [Related]
17. Relationship of systemic exposure to unbound docetaxel and neutropenia.
Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
[TBL] [Abstract][Full Text] [Related]
18. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
Pectasides D; Visvikis A; Kouloubinis A; Glotsos J; Bountouroglou N; Karvounis N; Ziras N; Athanassiou A
Eur J Cancer; 2002 Jun; 38(9):1194-200. PubMed ID: 12044505
[TBL] [Abstract][Full Text] [Related]
19. Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.
Hamberg P; Mathijssen RH; de Bruijn P; Leonowens C; van der Biessen D; Eskens FA; Sleijfer S; Verweij J; de Jonge MJ
Cancer Chemother Pharmacol; 2015 Feb; 75(2):365-71. PubMed ID: 25533184
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Dy GK; Mandrekar S; Peethambaram PP; Okuno SH; Croghan GC; Hanson LJ; Furth A; Adjei AA
Cancer Chemother Pharmacol; 2005 Dec; 56(6):623-8. PubMed ID: 15999272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
